References

Global burden of the key components of cardiovascular-kidney-metabolic syndrome

10.1681/asn.0000000658 · 2025 · External reference

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

10.1016/s0140-6736(18)32279-7 · 2018 · External reference

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

10.1016/s0140-6736(23)01301-6 · 2023 · External reference

Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults

10.1016/s0140-6736(23)02750-2 · 2024 · External reference

Cardiovascular-kidney-metabolic (CKM) syndrome: a state-of-the-art review

10.1016/j.cpcardiol.2023.102344 · 2024 · External reference

Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020

10.1001/jama.2024.6892 · 2024 · External reference

Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association

10.1161/cir.0000000000001184 · 2023 · External reference

The cardio-renal-metabolic connection: a review of the evidence

10.1186/s12933-023-01937-x · 2023 · External reference

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology

10.1093/eurheartj/ehy596 · 2018 · External reference

Role of diabetes in congestive heart failure: the Framingham study

10.1016/0002-9149(74)90089-7 · 1974 · External reference

Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

10.1161/cir.0000000000000691 · 2019 · External reference

Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes

10.1093/eurheartj/ehv134 · 2015 · External reference

2026 AHA/ACC/ADA/ASN Guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

10.1161/cir.0000000000001453 · 2026 · External reference

Cardiovascular–kidney–metabolic syndrome stages, echocardiographic characteristics, and heart failure risk: the atherosclerosis risk in communities study

10.1161/circulationaha.125.077894 · 2026 · External reference

Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association

10.1161/cir.0000000000001191 · 2023 · External reference

Cardiovascular disease in chronic kidney disease

10.1093/eurheartj/ehaf167 · 2025 · External reference

KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease

2024 · External reference

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

10.1172/jci200319451 · 2003 · External reference

Increased oxidative stress in obesity and its impact on metabolic syndrome

10.1172/jci21625 · 2004 · External reference

Human epicardial adipose tissue is a source of inflammatory mediators

10.1161/01.cir.0000099542.57313.c5 · 2003 · External reference

Adiponectin regulates albuminuria and podocyte function in mice

2008 · External reference

Biochemistry and molecular cell biology of diabetic complications

10.1038/414813a · 2001 · External reference

Oxidative stress and diabetic complications

10.1161/circresaha.110.223545 · 2010 · External reference

The interplay between diabetes, cardiovascular disease, and kidney disease

10.2337/db20211-13 · 2021 · External reference

The evolving concept from cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinology

10.1007/s11154-025-10013-6 · 2026 · External reference

Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

10.1159/000539371 · 2024 · External reference

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

10.1136/gutjnl-2020-320622 · 2020 · External reference

NAFLD as a driver of chronic kidney disease

10.1016/j.jhep.2020.01.013 · 2020 · External reference

Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis

10.1007/s00330-024-10798-1 · 2024 · External reference

Association of the non-alcoholic fatty liver disease fibrosis score with subclinical myocardial remodeling in patients with type 2 diabetes: a cross-sectional study in China

10.1111/jdi.13430 · 2021 · External reference

Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease

10.1007/s11739-022-02966-2 · 2022 · External reference

Cellular senescence, inflammaging and cardiovascular disease

10.1111/imr.70084 · 2026 · External reference

Aging at the crossroads of organ interactions: implications for the heart

10.1161/circresaha.125.325637 · 2025 · External reference

Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus

10.1016/j.jacc.2017.07.792 · 2017 · External reference

Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus

10.1016/j.echo.2014.01.001 · 2014 · External reference

Animal models for preclinical research on multifactorial human conditions: the case of cardiovascular-kidney-metabolic syndrome

10.1016/j.biopha.2025.118269 · 2025 · External reference

Translation animal models of diabetic kidney disease: biochemical and histological phenotypes, advantages and limitations

10.2147/dmso.s408170 · 2023 · External reference

The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas

10.33549/physiolres.930111 · 2001 · External reference

Impact of genetic background on nephropathy in diabetic mice

10.1152/ajprenal.00204.2005 · 2006 · External reference

Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model

10.1038/s41598-023-42670-5 · 2023 · External reference

SGLT2 Inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition

10.1016/j.cmet.2020.06.020 · 2020 · External reference

The gut microbiota and diabetes: research, translation, and clinical applications-2023 diabetes, diabetes care, and Diabetologia expert forum

2024 · External reference

Semaglutide in patients with heart failure with preserved ejection fraction and obesity

10.1056/nejmoa2306963 · 2023 · External reference

Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

10.1056/nejmoa2403347 · 2024 · External reference

GLP-1 and the cardiovascular system

10.1172/jci194748 · 2026 · External reference

Cardiovascular, kidney, liver, and metabolic interactions in heart failure: breaking down silos

10.1161/circresaha.125.325602 · 2025 · External reference

Empagliflozin in patients with chronic kidney disease

10.1056/nejmoa2204233 · 2023 · External reference

Clinical practice guideline for the evaluation and management of chronic kidney disease

2024 · External reference

Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)

10.2337/dci22-0027 · 2022 · External reference

Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care

10.1161/circoutcomes.120.007264 · 2020 · External reference

DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

10.1016/j.jdiacomp.2021.108101 · 2022 · External reference

2026 ESC guidelines for the management of cardiovascular disease and chronic kidney disease

10.1093/eurheartj/ehag098 · 2026 · External reference

2026 ESC guidelines for the management of heart failure

10.1093/eurheartj/ehag100 · 2026 · External reference

Evaluation, management and therapeutic approach of cardiovascular-kidney-metabolic syndrome: a multidisciplinary Delphi expert consensus

10.3390/jcm14248930 · 2025 · External reference

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction: SOLVD (Studies of Left Ventricular Dysfunction) investigators

10.1161/01.cir.88.5.2277 · 1993 · External reference

Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial

10.1001/jama.2023.2854 · 2023 · External reference

Impact of a multidisciplinary approach on cardiometabolic risk reduction in a multiracial cohort of adults: a 1-year pilot study

10.3390/nu14163391 · 2022 · External reference

Dapagliflozin in patients with chronic kidney disease

10.1056/nejmoa2024816 · 2020 · External reference

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis

10.1001/jamacardio.2020.4511 · 2021 · External reference

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes

10.1056/nejmoa2025845 · 2020 · External reference

Tirzepatide for heart failure with preserved ejection fraction and obesity

10.1056/nejmoa2410027 · 2025 · External reference

Cardiovascular events with finerenone in kidney disease and type 2 diabetes

10.1056/nejmoa2110956 · 2021 · External reference

Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus

10.1161/circulationaha.119.042685 · 2019 · External reference

2021 ESC guidelines on cardiovascular disease prevention in clinical practice

10.1093/eurheartj/ehab484 · 2021 · External reference

2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

10.1093/eurheartj/ehab368 · 2021 · External reference

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

10.2337/dc10-2415 · 2011 · External reference

Bariatric surgery and long-term cardiovascular events

10.1001/jama.2011.1914 · 2012 · External reference

Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients

10.1016/j.ypmed.2014.02.001 · 2014 · External reference

Weight can't wait: a guide to discussing obesity and organizing treatment in the primary care setting

10.1002/oby.23154 · 2021 · External reference

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

10.1016/s2213-8587(17)30412-6 · 2018 · External reference

A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association

10.1161/cir.0000000000001186 · 2023 · External reference

Effect of a multifactorial intervention on mortality in type 2 diabetes

10.1056/nejmoa0706245 · 2008 · External reference

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

10.1016/s0140-6736(11)60739-3 · 2011 · External reference

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study: SAVE investigators

10.1016/s0735-1097(96)00489-5 · 1997 · External reference

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2022 · External reference

Implementation barriers to evidence-based cardiovascular-kidney-metabolic syndrome management

10.1016/j.hlc.2025.05.095 · 2025 · External reference

Beyond siloed care: the promise and challenge of cardiovascular-kidney-metabolic syndrome

10.1161/circulationaha.126.080672 · 2026 · External reference

Integrating social determinants of health in the management of cardiovascular-kidney-metabolic syndrome

10.1161/jaha.124.036518 · 2024 · External reference

Disparities in SGLT2 inhibitor or glucagon-like peptide 1 receptor agonist initiation among medicare-insured adults with CKD in the United States

10.1016/j.xkme.2022.100564 · 2023 · External reference

Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study

2022 · External reference

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study

10.1016/j.eclinm.2024.102426 · 2024 · External reference

Total-body positron emission tomography: investigating mechanisms in cardiovascular-kidney-metabolic syndrome

10.1016/j.nuclcard.2025.102299 · 2025 · External reference

Renal fat accumulation assessed by MRI or CT and its association with clinical and metabolic disorders: a systematic imaging review

10.3390/jcm14124305 · 2025 · External reference

Transforming the cardiometabolic disease landscape: multimodal AI-powered approaches in prevention and management

10.1016/j.cmet.2024.02.002 · 2024 · External reference